|
Case
|
Age (mo)
|
BW (kg)
|
BSA (m2)
|
Diagnosis
|
Interval from BDG (mo)
|
Fenestration
|
ECC (mm)
|
Predicted m-V
|
IVC (mm)
|
Pharmacol. support (γ)
|
sBP
|
CVP
|
rSO2
|
ScvO2
|
Measured m-V
|
|---|
|
A
|
B
|
M
|
N
|
|---|
|
1
|
55
|
13.0
|
0.58
|
SLV
|
47
|
+
|
18
|
10.9
|
14.3
|
4
|
3
|
0.5
|
2
|
85
|
16.5
|
–
|
74.1
|
20.0
|
|
2
|
31
|
12.8
|
0.54
|
SLV
|
14
|
–
|
18
|
8.5
|
10.0
|
5
|
2
|
0.5
|
3
|
95
|
16
|
–
|
71.4
|
17.0
|
|
3
|
28
|
10.4
|
0.48
|
HLHS
|
14
|
–
|
16
|
9.7
|
9.8
|
4
|
5
|
0.5
|
2
|
105
|
16
|
–
|
86.9
|
38.3
|
|
4
|
54
|
14.4
|
0.63
|
d-TGA, PS
|
14
|
–
|
16
|
14.6
|
9.6
|
5
|
0
|
0.5
|
3
|
75
|
13.5
|
81/83
|
81.6
|
34.7
|
|
5
|
60
|
18.6
|
0.72
|
TA
|
55
|
+
|
18
|
13.4
|
10.0
|
5
|
2
|
0.5
|
3
|
90
|
16
|
85/89
|
–
|
36.3
|
|
6
|
37
|
12.2
|
0.55
|
unbalanced AVSD
|
15
|
–
|
16
|
11.5
|
7.2
|
3
|
0
|
0.5
|
1
|
90
|
14.5
|
78/80
|
–
|
18.7
|
|
7
|
29
|
11.2
|
0.50
|
SLV, DORV, AVSD
|
13
|
–
|
16
|
10.0
|
7.0
|
5
|
0
|
0.5
|
1
|
80
|
15
|
86/83
|
–
|
19.0
|
|
8
|
27
|
10.0
|
0.46
|
Ebstein’s anomaly
|
18
|
+
|
16
|
9.4
|
5.9
|
4
|
0
|
0.5
|
1
|
80
|
15
|
74/67
|
–
|
56.7
|
-
mo months, BW body weight, BSA body surface area, BDG bidirectional Glenn, ECC extra-cardiac conduit, m-V mean velocity, IVC inferior vena cava, pharmacol. pharmacological, γ μg/kg/min, A dopamine, B dobutamine, M milrinone, N nitroglycerine, sBP systolic blood pressure, CVP central venous pressure, rSO
2
cerebral regional oxygen saturation, ScvO
2
central venous oxygen saturation, SLV single left ventricle, HLHS hypoplastic left heart syndrome, TGA transposition of the great arteries, PS pulmonary stenosis, TA tricuspid atresia, AVSD atrioventricular septal defect, DORV double outlet from right ventricle
